title: Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for intraventricular hemorrhage: the CLEAR IVH Study Group.
abstract: OBJECTIVE
  This is the first prospective evaluation of changes in systemic hematologic status following administration of intraventricular recombinant tissue-type plasminogen activator in patients with intraventricular hemorrhage (IVH).
  
  
  METHODS
  Laboratory data from subjects enrolled onto the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) Trials were analyzed. We analyzed pre- and post- recombinant tissue-type plasminogen activator dosing coagulation parameters. Longer-term changes in hematologic status were studied in subjects who received the study agent after blood clot in the third/fourth ventricles had resolved radiologically.
  
  
  RESULTS
  Plasma fibrinogen increased significantly in both treatment groups. Dosing did not have a significant impact on any systemic coagulation parameters in either treatment group.
  
  
  CONCLUSIONS
  Intraventricular recombinant tissue-type plasminogen activator is unlikely to impact systemic coagulation or to compound the effects of systemic anticoagulation for deep venous thrombosis prophylaxis.
  
  
  BACKGROUND
  URL: http://clinicaltrials.gov. Unique identifier: NCT00650858.
authors.affiliation: Department of Neurology, Johns Hopkins University, School of Medicine, BA, 1550 Orleans Street, CRB-II 3M50, Baltimore, MD 21231, USA. daniel.herrick@tufts.edu
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Herrick
authors.forename: Wendy C
authors.initials: WC
authors.lastname: Ziai
authors.forename: Carol B
authors.initials: CB
authors.lastname: Thompson
authors.forename: Karen
authors.initials: K
authors.lastname: Lane
authors.forename: Nichol A
authors.initials: NA
authors.lastname: McBee
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Hanley
mesh_terms: D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects*; D002543:Cerebral Hemorrhage / Q000188:drug therapy* / Q000503:physiopathology; D002552:Cerebral Ventricles / Q000187:drug effects / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D012189:Retrospective Studies; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D005340:Fibrinogen; D010959:Tissue Plasminogen Activator